MCM
KYMR icon

MAI Capital Management’s Kymera Therapeutics KYMR Stock Holding History

MAI Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-929
Closed -$77.4K – 3512
2026
Q1 		$77.4K Buy
929
+5
+0.5% +$396 ﹤0.01% 1964
2025
Q4 		$71.9K Hold
924
– – ﹤0.01% 1814
2025
Q3 		$52.3K Hold
924
– – ﹤0.01% 1898
2025
Q2 		$40.3K Sell
924
-476
-34% -$16.4K ﹤0.01% 1982
2025
Q1 		$38.3K Hold
1,400
– – ﹤0.01% 1885
2024
Q4 		$56.3K Buy
+1,400
New +$63.2K ﹤0.01% 1707

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

MAI Capital Management's KYMR Position: Q2 2026 in Review

MAI Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 929 shares — an estimated $77.4K sold.

MAI Capital Management first reported a position in KYMR in Q4 2024 and held it in 6 quarters. The position peaked at $77.4K in Q1 2026. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • MAI Capital Management reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 929 Kymera Therapeutics shares in Q2 2026, an estimated $77.4K.
  • MAI Capital Management first reported a position in Kymera Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Kymera Therapeutics position peaked at $77.4K in Q1 2026.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.